Stocks · News reference
Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-16 AccNo: 0001193125-26-424052 Size: 252 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
CCC Intelligent Solutions shares surged 8% on Monday following reports that Elliott Investment Management and private equity firm GTCR are in advanced discussions to acquire the software company that serves the auto insurance industry. Bloomberg reported a deal could be announced this week, though no agreement has been finalized. Previously, Copart was also reported to be in acquisition talks with CCC.
CCC Intelligent Solutions surged 8% to $7.59 on October 12, 2026, following premarket reports of advanced acquisition talks with private equity firms GTCR and Elliott Management. The stock has gained 7% the previous Friday when acquisition rumors first emerged. With a current market cap of $4.2 billion, CCC remains over 40% below its 2023 all-time high, presenting potential upside if a deal is completed.
Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.
VanEck Biotech ETF (BBH) offers lower costs (0.35% expense ratio) and concentrated exposure to 25 large-cap biotech leaders, outperforming Invesco Biotechnology & Genome ETF (PBE) over the past year. However, PBE delivers higher dividend income (1.3% yield) and slightly better five-year returns through a multifactor selection strategy. BBH is ideal for cost-conscious momentum investors, while PBE suits those seeking income and a diversified factor-driven approach.